Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years


Buti M., Fung S., Gane E., Afdhal N. H. , Flisiak R., GÜREL S. , ...More

HEPATOLOGY INTERNATIONAL, vol.9, no.2, pp.243-250, 2015 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 9 Issue: 2
  • Publication Date: 2015
  • Doi Number: 10.1007/s12072-015-9614-4
  • Title of Journal : HEPATOLOGY INTERNATIONAL
  • Page Numbers: pp.243-250

Abstract

Phase 3 clinical studies have shown that long-term treatment with tenofovir disoproxil fumarate (TDF) can suppress hepatitis B viral load and promote significant fibrosis regression and cirrhosis reversal in a majority of treated chronic hepatitis B (CHB) patients. This retrospective analysis investigated the impact of baseline cirrhosis status on virologic, serologic, and histologic outcomes in patients treated with TDF.